Latest market price
20.06
-0.70-3.37%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.65 | Insider Own | 16.99% | Shs Outstand | 116.90M | Perf Week | 1.78% |
| Market Cap | 2.35B | Forward P/E | — | EPS next Y | -1.56 | Insider Trans | -1.90% | Shs Float | 81.50M | Perf Month | -16.97% |
| Enterprise Value | 1.71B | PEG | — | EPS next Q | -0.49 | Short Float | 17.31% | Perf Quarter | -27.03% | ||
| Income | -204.00M | P/S | 101.96 | EPS this Y | — | Short Ratio | 10.03 | Perf Half Y | -29.44% | ||
| Sales | 23.00M | P/B | 3.72 | EPS next Y | — | ROA | -36.84% | Short Interest | 14.11M | Perf YTD | -42.82% |
| Book/sh | 5.40 | P/C | 3.70 | EPS next 5Y | — | ROE | -38.33% | 52W High | 42.21 -52.48% | Perf Year | -44.03% |
| Cash/sh | 5.42 | P/FCF | — | EPS past 3/5Y | — | ROIC | -38.70% | 52W Low | 19.13 4.86% | Perf 3Y | 235.45% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -39.33% — | Gross Margin | 92.15% | Volatility | 5.27% 5.56% | Perf 5Y | 104.49% |
| Dividend TTM | — | EV/Sales | 74.40 | EPS Y/Y TTM | — | Oper. Margin | -3432.20% | ATR (14) | 1.22 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 9.03 | Sales Y/Y TTM | -89.06% | Profit Margin | -3644.21% | RSI (14) | 40.70 | Recom | 2.10 |
| Dividend Gr. 3/5Y | — | Current Ratio | 9.03 | EPS Q/Q | -246.67% | SMA20 | -4.16% | Beta | 0.13 | Target Price | 51.33 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | -78.95% | SMA50 | -12.25% | Rel Volume | 0.77 | Prev Close | 20.76 |
| Employees | 100 | LT Debt/Eq | 0.00 | Earnings | Nov 04 | SMA200 | -32.69% | Avg Volume | 1.48M | Price | 20.06 |
| IPO Date | Feb 09, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -9.01% 97.11% | Net Debt/EBITDA | — | Volume | 1,139,894 | Change | -3.37% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-20-26 | Initiated | BMO Capital | Outperform | $58 |
| Jul-20-26 | Reiterated | Jefferies | $45 | |
| Jun-30-26 | Reiterated | RBC Capital | Outperform | $47 → $51 |
| Feb-19-26 | Reiterated | Guggenheim | Buy | $45 |
| Jan-21-26 | Reiterated | RBC Capital | Outperform | $47 |
| Jan-06-26 | Reiterated | Leerink Partners | $45 → $55 | |
| Dec-02-25 | Reiterated | Goldman Sachs | Neutral | $37 |
| Oct-20-25 | Reiterated | H.C. Wainwright | Buy | $48 → $52 |
| Aug-25-25 | Initiated | Wells Fargo | Overweight | $45 |
| Mar-03-25 | Reiterated | UBS | $35 → $41 |
Latest News· Times ET
Oct-16-26
Oct-16-2603:41AM
Oct-13-26
Oct-13-2607:22PM
Oct-05-26
Oct-05-2605:32AM
Oct-02-26
Oct-02-2604:01PM
Sep-29-26
Sep-29-2608:00AM
Sep-23-26
Sep-23-2601:43PM
Sep-22-26
Sep-22-2609:20PM
Sep-21-26
Sep-21-2609:00AM
Sep-15-26
Sep-11-26
Sep-11-2603:45AM
Sep-08-26
Sep-04-26
Sep-04-2605:00PM
Sep-03-26
Sep-03-2604:01PM
Sep-02-26
Sep-02-2608:00AM
Aug-26-26
Aug-26-2608:00AM
Company
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 23 | 46 | 14 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | |
| Gross Profit | 22 | 46 | 14 | — | — | — | |
| Selling, General and Administrative Excl. Other | 106 | 70 | 38 | — | — | — | |
| Research and Development | 142 | 151 | 159 | — | — | — | |
| Other Operating Expense | 0 | 1 | 0 | — | — | — | |
| Operating Income | -226 | -176 | -183 | — | — | — | |
| Interest Expense | 0 | 0 | 7 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 22 | -65 | 13 | — | — | — | |
| Net Income Before Taxes | -204 | -242 | -177 | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -204 | -242 | -177 | — | — | — | |
| Net Income From Continuing Operations | -204 | -242 | -177 | — | — | — | |
| Net Income | -204 | -242 | -177 | — | — | — | |
| EPS (Recurring) | -1.75 | -2.56 | -2.15 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.75 | -2.56 | -2.15 | — | — | — | |
| EPS (Diluted) | -1.75 | -2.56 | -2.15 | — | — | — | |
| EBITDA | -242 | -241 | -177 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | 173.87 | 52.52 | 65.42 | — | — | — | |
| Gross Margin | 95.65 | 100.00 | 100.00 | — | — | — | |
| Operating Margin | -982.61 | -382.61 | -1,307.14 | — | — | — | |
| Net Margin | -886.96 | -526.09 | -1,264.29 | — | — | — | |
| Shares Outstanding | 114 | 94 | 82 | — | — | — | |
| Market Capitalization | 3,999 | 2,416 | 916 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Sep 30 '26 | Option Exercise | 0.00 | 50,246 | 0 | 119,548 | Oct 02 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Sep 30 '26 | Sale | 25.03 | 50,246 | 1,257,657 | 69,302 | Oct 02 |
| Davidson Michael H. | Chief Executive Officer | Sep 14 '26 | Buy | 22.65 | 10,000 | 226,500 | 792,923 | Sep 15 |
| Smither John W | Director | Sep 04 '26 | Sale | 25.32 | 1,600 | 40,512 | 8,760 | Sep 09 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Aug 24 '26 | Option Exercise | 0.00 | 125,000 | 0 | 194,302 | Aug 25 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Aug 24 '26 | Sale | 26.91 | 125,000 | 3,363,750 | 69,302 | Aug 25 |
| Kooij Louise Frederika | Chief Accounting Officer | Jul 20 '26 | Option Exercise | 11.34 | 105,000 | 1,191,100 | 129,353 | Jul 22 |
| Kooij Louise Frederika | Chief Accounting Officer | Jul 20 '26 | Sale | 30.34 | 105,000 | 3,185,656 | 24,353 | Jul 22 |
| Kooij Louise Frederika | Chief Accounting Officer | Jun 22 '26 | Option Exercise | 11.28 | 40,000 | 451,000 | 64,353 | Jun 24 |
| Kooij Louise Frederika | Chief Accounting Officer | Jun 22 '26 | Sale | 30.20 | 40,000 | 1,208,159 | 24,353 | Jun 24 |
| Kooij Louise Frederika | Chief Accounting Officer | May 26 '26 | Option Exercise | 10.07 | 65,000 | 654,500 | 89,353 | May 27 |
| Kooij Louise Frederika | Chief Accounting Officer | May 26 '26 | Sale | 35.69 | 65,000 | 2,319,850 | 24,353 | May 27 |
| LANGE LOUIS G | Director | Mar 11 '26 | Sale | 30.42 | 44,619 | 1,357,230 | 10,360 | Mar 12 |
| LANGE LOUIS G | Director | Mar 09 '26 | Option Exercise | 11.50 | 44,619 | 513,119 | 54,979 | Mar 10 |
| LANGE LOUIS G | Director | Mar 06 '26 | Sale | 29.41 | 28,186 | 828,950 | 0 | Mar 10 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.